ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Position Boosted by Natixis Advisors LLC

Natixis Advisors LLC boosted its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 43.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,527 shares of the biopharmaceutical company’s stock after purchasing an additional 7,697 shares during the period. Natixis Advisors LLC’s holdings in ACADIA Pharmaceuticals were worth $415,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter valued at $39,000. Covestor Ltd lifted its holdings in shares of ACADIA Pharmaceuticals by 70.5% in the first quarter. Covestor Ltd now owns 2,032 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 840 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of ACADIA Pharmaceuticals in the first quarter valued at $48,000. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter valued at $100,000. Finally, Shell Asset Management Co. lifted its holdings in shares of ACADIA Pharmaceuticals by 65.7% in the first quarter. Shell Asset Management Co. now owns 7,339 shares of the biopharmaceutical company’s stock valued at $136,000 after purchasing an additional 2,909 shares in the last quarter. 96.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, August 8th. Needham & Company LLC cut their target price on ACADIA Pharmaceuticals from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday, August 7th. Morgan Stanley lowered ACADIA Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $28.00 to $20.00 in a report on Wednesday, August 7th. UBS Group cut their target price on ACADIA Pharmaceuticals from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Finally, Royal Bank of Canada cut their target price on ACADIA Pharmaceuticals from $29.00 to $26.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Five equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, ACADIA Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $25.56.

ACADIA Pharmaceuticals Trading Up 2.3 %

ACAD stock opened at $16.32 on Friday. ACADIA Pharmaceuticals Inc. has a 12 month low of $14.55 and a 12 month high of $32.59. The stock has a market capitalization of $2.71 billion, a P/E ratio of -1,630.37, a price-to-earnings-growth ratio of 0.53 and a beta of 0.40. The firm has a 50-day moving average price of $16.90 and a 200-day moving average price of $17.15.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.02. ACADIA Pharmaceuticals had a net margin of 3.43% and a return on equity of 6.89%. The company had revenue of $241.96 million for the quarter, compared to analysts’ expectations of $235.95 million. During the same quarter in the previous year, the firm posted $0.01 earnings per share. ACADIA Pharmaceuticals’s revenue for the quarter was up 46.4% on a year-over-year basis. As a group, equities analysts predict that ACADIA Pharmaceuticals Inc. will post 0.52 EPS for the current fiscal year.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, COO Brendan Teehan sold 9,534 shares of the stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $15.28, for a total value of $145,679.52. Following the transaction, the chief operating officer now owns 52,177 shares in the company, valued at $797,264.56. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Stephen Davis sold 31,747 shares of the stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $15.28, for a total transaction of $485,094.16. Following the completion of the transaction, the chief executive officer now directly owns 186,555 shares of the company’s stock, valued at approximately $2,850,560.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Brendan Teehan sold 9,534 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $15.28, for a total value of $145,679.52. Following the completion of the transaction, the chief operating officer now owns 52,177 shares in the company, valued at approximately $797,264.56. The disclosure for this sale can be found here. Over the last three months, insiders have sold 51,014 shares of company stock valued at $779,494. 28.30% of the stock is currently owned by company insiders.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.